DENODO
23.6.2022 09:03:13 CEST | Business Wire | Press release
Denodo , the leader in data management, today announced that its customer LeasePlan, headquartered in the Netherlands and with business operations across the globe, has been chosen as the winner of the IDC’s 2022 European Data Strategy & Innovation Awards in the Data Management Excellence category. The winners were announced on June 9th, 2022 at the special awards ceremony as part of IDC’s 2022 European Data and Intelligence Summit in Sintra, Portugal.
IDC's European Data Strategy & Innovation Awards are focused on celebrating the European organizations that are blazing trails in this area and on improving awareness of "what works". According to Neil Ward-Dutton, VP AI, Automation and Analytics Europe, at IDC, "This is the third year of our European Data Strategy and Innovation Awards, and we were delighted to receive so many high-quality nominations from across the region."
IDC received 34 nominations for 3 award categories and LeasePlan edged past the other nominees in the Data Management excellence category to win the coveted title. According to IDC, "Nominations in this category were from enterprises that could demonstrate significant advances in their ability to manage data effectively and efficiently at scale. The overall winner was LeasePlan, for its creation of a logical data fabric across all its key data sources, which has helped the company in creating transformational new use cases in customer experience and convenience, such as predictive vehicle maintenance programs."
LeasePlan, one of the world’s leading Car-as-a-Service companies, has approximately 1.9 million vehicles under management in 29 countries. These vehicles generate a large amount of data that has to be integrated and contextualized to support the customer journey. What followed was LeasePlan’s next-gen data strategy, envisioned to encompass a logical data fabric across all its key data sources – modern, cloud-based and legacy – with a single point of access, to be supported by a Global Data Hub. According to Sumit Arya, the Head of Data and Solution Architecture at LeasePlan, “The Logical Data Fabric built on the Denodo Platform is a critical component of LeasePlan’s Global Data Hub to seamlessly build a foundation for data self-service and simplify transparent data migration. It has enabled us to create new business services and best support our drivers on every step of their journey.” Denodo Platform has also supported the data governance needs of the organization and facilitated its cloud modernization efforts with zero downtime for BI reporting while migrating legacy data marts to the Cloud in various business units across geographies.
“We want to congratulate our customer LeasePlan for its efforts and the innovative use of the Denodo Platform to support its data management needs and key business initiatives,” said Ravi Shankar, Senior Vice President and Chief Marketing Officer at Denodo. “The Denodo Platform provides an abstraction layer to create a single, secure point-of-entry to LeasePlan's entire data ecosystem. LeasePlan has also built a centralized framework for data governance by leveraging the metadata management and data catalog capabilities of the Denodo platform to ensure the highest level of self-service and data security. We are thrilled to see LeasePlan credited for the way they have applied our platform to make such an impact.”
Please Tweet : https://ctt.ac/hUnsp
About LeasePlan
LeasePlan, one of the world’s leading Car-as-a-Service companies, is transforming from an analogue to a fully digital business model. LeasePlan worked with Denodo and other technologies to create a logical data fabric across all its key data sources – modern, cloud-based and legacy – with a single point of access. This gives a foundation for data self-service and simplifies transparent data migration to the Cloud. Most notably, the data fabric approach has helped the company in creating transformational new use cases in customer experience and convenience, such as predictive vehicle maintenance programs.
About Denodo
Denodo is a leader in data management. The award-winning Denodo Platform is the leading data integration, management, and delivery platform using a logical approach to enable self-service BI, data science, hybrid/multi-cloud data integration, and enterprise data services. Realizing more than 400% ROI and millions of dollars in benefits, Denodo’s customers across large enterprises and mid-market companies in 30+ industries have received payback in less than 6 months. For more information, visit www.denodo.com or call +1 877 556 2531 (US) / +44 (0) 20 7869 8053 (UK) / +65 6950 7489 (Singapore).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005168/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom